Compare OTTR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTTR | ELVN |
|---|---|---|
| Founded | 1907 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 2009 | 2020 |
| Metric | OTTR | ELVN |
|---|---|---|
| Price | $75.31 | $48.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $88.00 | $74.33 |
| AVG Volume (30 Days) | 212.9K | ★ 1.5M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 2.95 | N/A |
| Revenue | ★ $1,299,640,000.00 | N/A |
| Revenue This Year | $0.88 | N/A |
| Revenue Next Year | $1.92 | N/A |
| P/E Ratio | $25.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $75.50 | $14.79 |
| 52 Week High | $95.09 | $62.32 |
| Indicator | OTTR | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 22.58 | 56.91 |
| Support Level | N/A | $44.18 |
| Resistance Level | $91.02 | $52.39 |
| Average True Range (ATR) | 2.63 | 2.31 |
| MACD | -1.31 | 0.99 |
| Stochastic Oscillator | 0.00 | 67.56 |
Otter Tail Corp is a U.S. energy company that operates in the electric (produces and sells electricity), manufacturing (fabricates metal components), and plastics segments (pipes for water uses). The company conducts its operations and acquires the majority of its revenue in the U.S. in the states of Minnesota, South Dakota, and North Dakota. The majority of the company's revenue is derived from the Electric segment and commercial customers, although it generates revenue from residential and industrial customers, as well.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.